The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Official Title: A Prospective Multicenter Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors
Study ID: NCT04892498
Brief Summary: This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Peking University Third Hospital, Beijing, , China
Hunan Cancer Hospital, Changsha, , China
The Second Xiangya Hospital of Central South University, Changsha, , China
Xiangya Hospital of Central South University, Changsha, , China
Chongqing University Cancer Hospital, Chongqing, , China
The Sixth Affiliated Hospital ,Sun Yat-seen University, Guangzhou, , China
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, , China
The First Affiliated Hospital of USTC, Hefei, , China
Shandong Provincial Tumor Hospital, Jinan, , China
The Second Affiliated Hospital of Nanchang University, Nanchang, , China
Jiangsu Cancer Hospital, Nanjing, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Second Affiliated Hospital of Soochow University, Suzhou, , China
Renmin Hospital of Wuhan University, Wuhan, , China
Jiangyin People's Hospital, Wuxi, , China
The Affilated Hospital of Xuzhou Medical University, Xuzhou, , China
Name: Liyuan Zhang, Dr
Affiliation: Second Affiliated Hospital of Soochow University
Role: PRINCIPAL_INVESTIGATOR